People Are Using an Unapproved Weight-Loss Drug—AI Analysis Reveals Surprising Symptom Reports
Date: October 21, 2026
Source: University of Pennsylvania School of Engineering and Applied Science
Summary
Researchers analyzing nearly 150,000 Reddit posts uncovered unexpected symptom reports linked by users to unapproved versions of retatrutide—including increased appetite, sleep disturbances, and elevated heart rates. The findings differ from clinical trial results and highlight how AI could help identify potential drug safety signals that warrant further investigation.
Full Story
An experimental weight-loss drug that has not yet received regulatory approval is already attracting users willing to obtain unapproved versions online. Now, scientists are using artificial intelligence to investigate their experiences—uncovering unexpected symptom reports that differ from those documented in clinical trials.
The drug, retatrutide, belongs to a new generation of GLP-1 medications designed to help regulate appetite and body weight. Although it remains under investigation and is not approved for use, people are purchasing unapproved formulations that are not intended for human consumption and discussing their experiences on internet forums.
Researchers at the University of Pennsylvania analyzed nearly 150,000 Reddit posts and comments from approximately 40,000 users to investigate these accounts. Their study, published in JAMA Network Open, provides the first systematic examination of potential side effects reported by people claiming to use unapproved retatrutide.
AI Uncovers Unexpected Findings
One finding stood out. Among users whose reported symptoms could be classified, increased appetite was the most common complaint. That was particularly unexpected because retatrutide is designed to suppress hunger, and its Phase 2 clinical trials primarily identified digestive problems as the most frequent side effects.
"Our goal is to identify hypotheses in online conversations that we could test. AI helps us find recurring patterns in people's self-reports, including experiences that may be missed by conventional drug-safety monitoring," says Sharath Chandra Guntuku, Research Associate Professor in Computer and Information Science (CIS), Director of Penn's Computational Social Listening Lab, and senior author of the study.
Why It Matters in 2026
The findings arrive at a pivotal moment. As GLP-1 drugs continue to dominate the weight-loss market in 2026, demand for next-generation compounds like retatrutide has surged—even before regulatory approval. This creates a gray market where unapproved formulations circulate online, often with uncertain purity, dosing, and safety profiles.
Traditional pharmacovigilance relies on formal reporting systems and controlled trials, both of which lag behind real-world use of unapproved drugs. The Penn study demonstrates how AI-driven analysis of public online discussions can act as an early-warning system—surfacing potential safety signals that might otherwise go undetected until formal trials or adverse-event reports catch up.
Looking Ahead
The researchers emphasize that these self-reported Reddit accounts are not clinical evidence. Instead, they serve as hypothesis-generating signals that merit follow-up in controlled settings. As unapproved GLP-1 use continues to grow, integrating AI-powered social listening into drug-safety surveillance could become an increasingly valuable complement to traditional monitoring—helping regulators and researchers spot emerging risks faster.
AI analysis of nearly 150,000 Reddit posts reveals surprising symptom reports surrounding an unapproved weight-loss drug, including increased appetite despite its intended appetite-suppressing effects.